Latest Breaking News On - Neuroendocrine prostate cancer - Page 1 : comparemela.com

Business Update | Company Announcement

Investegate announcements from Business Update

United kingdomSan diegoUnited statesCity ofComunidad autonoma de catalunaLucy whartonInaphaea biolabsSue carrInaphaea pdcsDamon heathDirectors of the companyImperial college londonCairn financial advisersEuropean union withdrawalShard capital partnersDundee university

HPN328 Shows Clinical Activity and Tolerability in Neuroendocrine Prostate Cancer

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

United statesDana farber cancer instituteHimisha beltranLank centerDivision of molecularOncology at dana farber cancer instituteTranslational researchGenitourinary oncologyCellular oncologyMedical oncologyNeuroendocrine prostate cancer2024 genitourinary cancers symposium

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral . Seite 1

United statesSan franciscoHimisha beltranDrug administrationMd dana farber cancer instituteHarpoon therapeutics incHarpoon therapeutics abstractRapid oral presentationClinical oncology genitourinary cancers symposiumAmerican societyActivating constructT cell engagerNeuroendocrine prostate cancerNeuroendocrine neoplasmsRapid oral abstract sessionProstate cancer

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Helen ogormanMatt ventimigliaBioxcel therapeutics incGenitourinary tumorsNeuroendocrine prostate cancerBioxcel therapeuticsXcel therapeutics

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Helen ogormanMatt ventimigliaCompany nasdaqBioxcel therapeutics incEuropean society for medical oncologyBioxcel therapeuticsMedical oncologyGenitourinary tumorsNeuroendocrine prostate cancerXcel therapeutics